Zhang Chengliang, Xu Yanjiao, Zhong Qiaoni, Li Xiping, Gao Ping, Feng Chengyang, Chu Qian, Chen Yuan, Liu Dong
Department of Pharmacy, Tongji hospital, Tongji medical school, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Hubei Pharmaceutical Industry Research Institute Co. Ltd., Wuhan, Hubei, China.
PLoS One. 2014 Apr 3;9(4):e93819. doi: 10.1371/journal.pone.0093819. eCollection 2014.
Two major forms of human carboxylesterase (CES), CES1A and CES2, dominate the pharmacokinetics of most prodrugs such as imidapril and irinotecan (CPT-11). Excipients, largely used as insert vehicles in formulation, have been recently reported to affect drug enzyme activity. The influence of excipients on the activity of CES remains undefined. In this study, the inhibitory effects of 25 excipients on the activities of CES1A1 and CES2 were evaluated. Imidapril and CPT-11 were used as substrates and cultured with liver microsomes in vitro. Imidapril hydrolase activities of recombinant CES1A1 and human liver microsomes (HLM) were strongly inhibited by sodium lauryl sulphate (SLS) and polyoxyl 40 hydrogenated castor oil (RH40) [Inhibition constant (Ki) = 0.04 ± 0.01 μg/ml and 0.20 ± 0.09 μg/ml for CES1A1, and 0.12 ± 0.03 μg/ml and 0.76 ± 0.33 μg/ml, respectively, for HLM]. The enzyme hydrolase activity of recombinant CES2 was substantially inhibited by Tween 20 and polyoxyl 35 castor oil (EL35) (K(i) = 0.93 ± 0.36 μg/ml and 4.4 ± 1.24 μg/ml, respectively). Thus, these results demonstrate that surfactants such as SLS, RH40, Tween 20 and EL35 may attenuate the CES activity; such inhibition should be taken into consideration during drug administration.
人类羧酸酯酶(CES)的两种主要形式,即CES1A和CES2,在大多数前体药物(如咪达普利和伊立替康(CPT - 11))的药代动力学中起主导作用。辅料在制剂中主要用作填充载体,最近有报道称其会影响药物酶活性。辅料对CES活性的影响尚不清楚。在本研究中,评估了25种辅料对CES1A1和CES2活性的抑制作用。以咪达普利和CPT - 11为底物,与肝微粒体进行体外培养。十二烷基硫酸钠(SLS)和聚氧乙烯40氢化蓖麻油(RH40)对重组CES1A1和人肝微粒体(HLM)的咪达普利水解酶活性有强烈抑制作用[CES1A1的抑制常数(Ki)= 0.04±0.01μg/ml和0.20±0.09μg/ml,HLM的抑制常数分别为0.12±0.03μg/ml和0.76±0.33μg/ml]。吐温20和聚氧乙烯35蓖麻油(EL35)对重组CES2的酶水解活性有显著抑制作用(K(i)分别为0.93±0.36μg/ml和4.4±1.24μg/ml)。因此,这些结果表明,SLS、RH40、吐温20和EL35等表面活性剂可能会减弱CES活性;在给药过程中应考虑这种抑制作用。